Work Loss in Relation to Pharmacological and Surgical Treatment for Crohn’s Disease: A Population-Based Cohort Study

Changes in inflammatory bowel disease subtype during follow-up and over time in 44,302 patients

(2019) Åsa H. Everhov et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Fracture Risk in Patients With Inflammatory Bowel Disease

(2019) Jonas F. Ludvigsson et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

The longitudinal integrated database for health insurance and labour market studies (LISA) and its use in medical research

(2019) Jonas F. Ludvigsson et al.   EUROPEAN JOURNAL OF EPIDEMIOLOGY

Mortality in adult-onset and elderly-onset IBD: a nationwide register-based cohort study 1964–2014

(2019) Ola Olén et al.   GUT

The Role of Early Biologic Therapy in Inflammatory Bowel Disease

(2019) Dana Rachel Berg et al.   INFLAMMATORY BOWEL DISEASES

Incidence and Treatment of Patients Diagnosed With Inflammatory Bowel Diseases at 60 Years or Older in Sweden

(2018) Åsa H. Everhov et al.   GASTROENTEROLOGY

Sick Leave and Disability Pension in Prevalent Patients With Crohn’s Disease

(2018) Åsa H Everhov et al.   Journal of Crohns & Colitis

Work Loss Before and After Diagnosis of Crohn’s Disease

(2018) Åsa H Everhov et al.   INFLAMMATORY BOWEL DISEASES

Prevalence of- and risk factors for work disability in Dutch patients with inflammatory bowel disease

(2017) Lieke M Spekhorst et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Registers of the Swedish total population and their use in medical research

(2016) Jonas F. Ludvigsson et al.   EUROPEAN JOURNAL OF EPIDEMIOLOGY

Clinical status, quality of life, and work productivity in Crohn’s disease patients after one year of treatment with adalimumab

(2016) Cristina Saro et al.   REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS

Unknown

(2016)   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Efficacy and Safety of Adalimumab in Canadian Patients with Moderate to Severe Crohn’s Disease: Results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn’s DiseaSe (ACCESS) Trial

(2016) Remo Panaccione et al.   CANADIAN JOURNAL OF GASTROENTEROLOGY

Effect of Adalimumab on Work Productivity and Indirect Costs in Moderate to Severe Crohn’s Disease: A Meta-Analysis

(2016) David G Binion et al.   CANADIAN JOURNAL OF GASTROENTEROLOGY

Implications of Infliximab Treatment Failure and Influence of Personalized Treatment on Patient-reported Health-related Quality of Life and Productivity Outcomes in Crohn’s Disease

(2015) Casper Steenholdt et al.   Journal of Crohns & Colitis

IBD-related work disability in the community: Prevalence, severity and predictive factors. A cross-sectional study

(2015) Alexis Ramos et al.   United European Gastroenterology Journal

Permanent Work Disability in Crohn's Disease

(2013) Ashwin N Ananthakrishnan et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: Results from the CARE trial

(2012) Edouard Louis et al.   Journal of Crohns & Colitis

Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn’s disease with prior loss of response to infliximab

(2011) B. G. Feagan et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

External review and validation of the Swedish national inpatient register

(2011) Jonas F Ludvigsson et al.   BMC PUBLIC HEALTH

Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn’s disease in the PRECiSE 2 study

(2010) B. G. FEAGAN et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research

(2009) Jonas F. Ludvigsson et al.   EUROPEAN JOURNAL OF EPIDEMIOLOGY